1. Duan,J., et al., Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis. JAMA Oncol,2019. 2. Ni Zhang, et al. Programmed cell death-1/programmed cell death ligand-1 checkpoint inhib...
[6].Yucai Wang, Shouhao Zhou, Fang Yang, et al. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis[J]. JAMA Oncol. 2019 Jul 1;5(7):1008-1019.
从研究结果来看:PD-1抑制剂在总生存和无疾病进展方面要略优于PD-L1抑制剂,两者在安全性方面没有太明显的差异[11]。 简单来说,PD-1抑制剂与PD-L1抑制剂没有太大区别。 但一些研究认为PD-L1抑制剂只阻断PD-1与PD-L1的结合,并不影响PD-1与PD-L2...
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis[J]. JAMA Oncol. 2019 Jul 1;5(7):1008-1019. 7、Rathi N Pillai, Madhusmita Behera, Taofeek K Owonikoko, et al. Comparison of the toxicity profile of PD-1 versus PD...
3.田季平, 张剑, 周金培,等. 免疫检查点PD-1/PD-L1小分子抑制剂的研究进展[J]. 中国药科大学学报, 2019. 4.Wu, Q., Jiang, L., Li, Sc. et al. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway. Acta Pharmacol Sin 42, 1–9 (2021). ...
在HTRF 实验中,其代表性化合物10(MAX-10181)、11 、12的IC50 分别为18 、46和18 nmol/L。再极医药的MAX-10181是全球第三个进入临床试验的小分子PDL1抑制剂,于2019年10月10日在澳洲开始一期临床试验。 芳香乙烯联苯类PD-1/PD-L1 小分子抑制剂(来源:文献3、9)...
1. Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. 2. Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer? 3. Resistance to immune checkpoint inhibitors. Next steps and combina...
2018年美国SEER(surveillance, epidemiology, and end results)数据库的数据显示,肺癌患者总体5年生存率为18.6%,而发生远处转移的晚期肺癌患者5年生存率仅为4.7%。随着免疫检查点抑制剂(Immune checkpoint inhibitors,ICI)的出现,晚期肺癌患者的5年生存率首次提高到了16%,相比4.7%提高了近3倍。仅2017年9月至2018年9...
3.^ Jump up to:a b c d Sunshine J, Taube JM (August 2015). 'PD-1/PD-L1inhibitors'. CurrentOpinion in Pharmacology. 23: 32-. doi:10.1016/j.coph.2015.05.011. PMC 4516625. PMID 26047524. 4.Ishida Y, AgataY, Shibahara K and Honjo T. Induced expression of PD-1, a novel member...
[17]FENG Z, RONG P, WANG W. Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors administered alone or in combination with anti-VEGF agents in advanced hepatocellular carcinoma[J]. Gut, 2020, 69(10): 1904-1906. DOI: 10.1136/gutjnl-2019-320116 [18]KUDO M. Immuno-...